EP1766017A4 - Tumor specific antibody - Google Patents

Tumor specific antibody

Info

Publication number: EP1766017A4
Authority: EP; European Patent Office
Prior art keywords: specific antibody; tumor specific; tumor; antibody; specific
Prior art date: 2004-06-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP05754865A

Other languages

German (de)

French (fr)

Other versions

EP1766017B1 (en

EP1766017A1 (en

Inventor

Nicholas Ronald Glover

Glen Christopher Macdonald

Joycelyn Entwistle

Jeannick Cizeau

Denis Georges Bosc

Francina C Chahal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Viventia Bio Inc

Original Assignee

Viventia Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-10

Filing date

2005-06-10

Publication date

2009-12-02

2005-06-10 Application filed by Viventia Biotech Inc filed Critical Viventia Biotech Inc

2005-06-10 Priority to EP14198378.3A priority Critical patent/EP2927322A1/en

2005-06-10 Priority to PL05754865T priority patent/PL1766017T3/en

2007-03-28 Publication of EP1766017A1 publication Critical patent/EP1766017A1/en

2009-12-02 Publication of EP1766017A4 publication Critical patent/EP1766017A4/en

2015-01-21 Application granted granted Critical

2015-01-21 Publication of EP1766017B1 publication Critical patent/EP1766017B1/en

Status Not-in-force legal-status Critical Current

2025-06-10 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44

EP05754865.3A 2004-06-10 2005-06-10 Tumor specific antibody Not-in-force EP1766017B1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP14198378.3A EP2927322A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody
PL05754865T PL1766017T3 (en)	2004-06-10	2005-06-10	Tumor specific antibody

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57829104P	2004-06-10	2004-06-10
PCT/CA2005/000899 WO2005121341A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP14198378.3A Division-Into EP2927322A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody
EP14198378.3A Division EP2927322A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody

Publications (3)

Publication Number	Publication Date
EP1766017A1 EP1766017A1 (en)	2007-03-28
EP1766017A4 true EP1766017A4 (en)	2009-12-02
EP1766017B1 EP1766017B1 (en)	2015-01-21

Family

ID=35503067

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP14198378.3A Withdrawn EP2927322A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody
EP05754865.3A Not-in-force EP1766017B1 (en)	2004-06-10	2005-06-10	Tumor specific antibody

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP14198378.3A Withdrawn EP2927322A1 (en)	2004-06-10	2005-06-10	Tumor specific antibody

Country Status (11)

Country	Link
US (3)	US8383117B2 (en)
EP (2)	EP2927322A1 (en)
JP (2)	JP5026268B2 (en)
CN (1)	CN101044242B (en)
AU (1)	AU2005252275B2 (en)
CA (1)	CA2569788C (en)
ES (1)	ES2535229T3 (en)
IL (1)	IL179891A (en)
NZ (1)	NZ552476A (en)
PL (1)	PL1766017T3 (en)
WO (1)	WO2005121341A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2382990B1 (en)	2003-04-30	2014-09-17	Universität Zürich	Methods for treating cancer using an immunotoxin
EA010803B1 (en)	2004-03-19	2008-12-30	Мерк Патент Гмбх	Modified bouganin proteins, cytotoxins and methods and uses thereof
EP1969165A4 (en) *	2005-12-23	2010-05-19	Viventia Biotech Inc	Methods for generating and screening fusion protein libraries and uses thereof
WO2008128330A1 (en) *	2007-04-19	2008-10-30	Viventia Biotech Inc.	Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
GB0718045D0 (en) *	2007-09-14	2007-10-24	Peptcell Ltd	Pharmaceutical compound
WO2009039630A1 (en)	2007-09-27	2009-04-02	Viventia Biotech Inc.	Optimized nucleic acid sequences for the expression of vb4-845
US20110002846A1 (en) *	2007-12-21	2011-01-06	Univeristy of Rochester	Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
US20100009390A1 (en) *	2008-05-09	2010-01-14	The Regents Of The University Of California	Mutant antibodies with high affinity for egfr
US20100008978A1 (en) *	2008-05-09	2010-01-14	The Regents Of The University Of California	Nanoparticles effective for internalization into cells
TWI404931B (en) *	2009-02-20	2013-08-11	Nat Synchrotron Radiation Res Ct	Method for cancer detection and reagent use for therein
JP6041333B2 (en) *	2011-01-13	2016-12-07	学校法人近畿大学	Antitumor agent
DK3729958T3 (en) *	2013-03-15	2023-08-07	Mayo Found Medical Education & Res	IDENTIFICATION AND MONITORING OF MONOCLONAL IMMUNOGLOBULINS USING MOLECULAR MASS
CN112472699A (en)	2013-07-26	2021-03-12	种族肿瘤学公司	Combination methods for improving the therapeutic benefit of bisantrene and derivatives
MX2016004239A (en)	2013-10-02	2016-11-14	Viventia Bio Inc	Anti-epcam antibodies and methods of use.
JP6759104B2 (en)	2014-04-04	2020-09-23	メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ	Immunoglobulin isotyping using precise molecular mass
EP3175242A4 (en)	2014-07-29	2017-12-27	Mayo Foundation for Medical Education and Research	Quantifying monoclonal antibody therapeutics by lc-ms/ms
WO2016068294A1 (en) *	2014-10-31	2016-05-06	株式会社カネカ	Method for manufacturing polypeptide including protein-synthesis-inhibiting protein toxin
WO2016145349A1 (en)	2015-03-12	2016-09-15	Viventia Bio Inc.	Methods of treatment for epcam positive bladder cancer
AU2016228760B2 (en)	2015-03-12	2020-07-16	Viventia Bio Inc.	Dosing strategies for targeting EPCAM positive bladder cancer
WO2016187571A2 (en) *	2015-05-20	2016-11-24	Viventia Bio Inc.	Her2 immunotoxins and methods of using the same
RU2022100330A (en)	2015-08-12	2022-01-19	Онкотерапи Сайенс, Инк.	PEPTIDE DERIVED FROM DEPDC1 AND VACCINE CONTAINING IT
US11209439B2 (en)	2015-09-24	2021-12-28	Mayo Foundation For Medical Education And Research	Identification of immunoglobulin free light chains by mass spectrometry
CN105510586B (en) *	2015-12-22	2017-09-12	湖北鹊景生物医学有限公司	Kit and its application method for pulmonary cancer diagnosis
CN109863395B (en)	2016-09-07	2023-05-23	梅约医学教育与研究基金会	Molecular weight method for identifying and monitoring cracked immunoglobulin
EP3681528A4 (en)	2017-09-13	2021-07-21	Mayo Foundation for Medical Education and Research	Identification and monitoring of apoptosis inhibitor of macrophage
CN109324189B (en) *	2018-08-15	2021-10-01	泰达国际心血管病医院	Application of polyprotein composition and congenital heart disease screening kit
CN111138521B (en) *	2018-11-06	2022-10-28	香雪生命科学技术（广东）有限公司	Short peptides derived from AFP antigen
EP3806895B1 (en) *	2019-02-15	2023-06-21	Atreca, Inc.	Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
CN112300261B (en) *	2019-07-23	2023-03-17	香雪生命科学技术（广东）有限公司	Tumor antigen short peptide derived from AFP
CN112851811B (en) *	2021-01-28	2022-08-09	姜国胜	CD44V6 nano antibody and application thereof as leukemia research reagent
CN114773478B (en) *	2022-03-14	2023-05-23	深圳市国创纳米抗体技术有限公司	anti-AFP antigen VHH domain and bispecific antibody containing same
WO2024040194A1 (en)	2022-08-17	2024-02-22	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
CN116297727B (en) *	2022-09-13	2024-01-23	山东大学齐鲁医院	Preparation and application of alpha fetoprotein and abnormal prothrombin electroluminescent sensor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863540A (en) *	1991-03-15	1999-01-26	Duke University	Adhesion molecule

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4736866A (en)	1984-06-22	1988-04-12	President And Fellows Of Harvard College	Transgenic non-human mammals
CN1042940A (en) *	1988-12-01	1990-06-13	中国农业科学院哈尔滨兽医研究所	Sick horse of equine infectious anemia and the serum antibody differential diagnosis reagent of inoculating the attenuated vaccine horse
WO1990010457A1 (en)	1989-03-14	1990-09-20	New York University	Method of treating hiv infections using immunotoxins
CN1075208A (en) *	1992-12-02	1993-08-11	张昌卿	A kind of chromogenic reagent and manufacture method thereof that detects Epstein-Barr virus antibody
US6197582B1 (en)	1998-03-18	2001-03-06	The Trustees Of Columbia University In The City Of New York	Development of human monoclonal antibodies and uses thereof
JP2003299497A (en) *	2002-02-05	2003-10-21	Masayoshi Kachi	Mucopolysaccharide and method for producing the same
WO2003066830A2 (en) *	2002-02-08	2003-08-14	Genetastix Corporation	Human monoclonal antibodies against membrane proteins
RS53476B (en) *	2003-07-18	2014-12-31	Amgen Fremont Inc.	Specific binding agents to hepatocyte growth factor
EA010803B1 (en)	2004-03-19	2008-12-30	Мерк Патент Гмбх	Modified bouganin proteins, cytotoxins and methods and uses thereof
US8802442B2 (en)	2011-11-30	2014-08-12	Eric B. Wheeldon	Apparatus and method for the remote sensing of blood in human feces and urine

2005
- 2005-06-10 WO PCT/CA2005/000899 patent/WO2005121341A1/en active Application Filing
- 2005-06-10 AU AU2005252275A patent/AU2005252275B2/en not_active Ceased
- 2005-06-10 NZ NZ552476A patent/NZ552476A/en not_active IP Right Cessation
- 2005-06-10 PL PL05754865T patent/PL1766017T3/en unknown
- 2005-06-10 US US11/570,198 patent/US8383117B2/en not_active Expired - Fee Related
- 2005-06-10 CA CA2569788A patent/CA2569788C/en not_active Expired - Fee Related
- 2005-06-10 EP EP14198378.3A patent/EP2927322A1/en not_active Withdrawn
- 2005-06-10 JP JP2007526144A patent/JP5026268B2/en not_active Expired - Fee Related
- 2005-06-10 CN CN2005800272005A patent/CN101044242B/en not_active Expired - Fee Related
- 2005-06-10 ES ES05754865.3T patent/ES2535229T3/en active Active
- 2005-06-10 EP EP05754865.3A patent/EP1766017B1/en not_active Not-in-force
2006
- 2006-12-06 IL IL179891A patent/IL179891A/en not_active IP Right Cessation
2012
- 2012-03-30 JP JP2012078467A patent/JP2012187104A/en active Pending
2013
- 2013-01-17 US US13/743,672 patent/US8969540B2/en active Active
2015
- 2015-01-23 US US14/604,047 patent/US20150197575A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863540A (en) *	1991-03-15	1999-01-26	Duke University	Adhesion molecule

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHAHAL F C ET AL: "A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab<(>TM) PF-2D in tandem with mass spectrometry", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 348, no. 3, 29 September 2006 (2006-09-29), pages 1055 - 1062, XP024924335, ISSN: 0006-291X, [retrieved on 20060929] *
DROLL ARMIN ET AL: "Adhesive interactions between alternatively spliced CD44 isoforms", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 19, 1995, pages 11567 - 11573, XP002551717, ISSN: 0021-9258 *
ICZKOWSKI K A ET AL: "PROSTATE CANCER OVEREXPRESSES CD44 VARIANTS 7-9 AT THE MESSENGER RNA AND PROTEIN LEVEL", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 4, 1 July 2003 (2003-07-01), pages 3129 - 3140, XP009071926, ISSN: 0250-7005 *
KARMALI A ET AL: "Human alfa-fetoprotein: isolation and production of monoclonal antibodies", BIOCHIMIE, MASSON, PARIS, FR, vol. 72, no. 5, 1 May 1990 (1990-05-01), pages 369 - 374, XP023479868, ISSN: 0300-9084, [retrieved on 19900501] *
NAOR D ET AL: "CD44:STRUCTURE, FUNCTION, AND ASSOCIATION WITH THE MALIGNANT PROCESS", ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 71, 1 January 1997 (1997-01-01), pages 241 - 319, XP000952636, ISSN: 0065-230X *
OKAMOTO ISAMU ET AL: "Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variants RNAs", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 90, no. 4, 18 February 1998 (1998-02-18), pages 307 - 315, XP002551716, ISSN: 0027-8874 *
ORTEU C H ET AL: "CD44 variant expression in cutaneous T-cell lymphoma", JOURNAL OF CUTANEOUS PATHOLOGY, BLACKWELL MUNKSGAARD, COPENHAGEN, DK, vol. 24, no. 6, 1 July 1997 (1997-07-01), pages 342 - 349, XP009124472, ISSN: 0303-6987 *
SASAKI JI-ICHIRO ET AL: "Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 12, no. 3, March 1998 (1998-03-01), pages 525 - 533, XP009124465, ISSN: 1019-6439 *
See also references of WO2005121341A1 *
SEKI KENICHIRO ET AL: "Inhibition of liver metastasis formation by anti-CD44 variant exon 9 monoclonal antibody", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 11, no. 6, December 1997 (1997-12-01), pages 1257 - 1261, XP009124463, ISSN: 1019-6439 *
YAMAGUCHI AKIO ET AL: "Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection", ONCOLOGY (BASEL), vol. 55, no. 5, September 1998 (1998-09-01), pages 400 - 404, XP009124461, ISSN: 0030-2414 *

Also Published As

Publication number	Publication date
JP2008508903A (en)	2008-03-27
US20150197575A1 (en)	2015-07-16
NZ552476A (en)	2009-09-25
AU2005252275B2 (en)	2011-07-21
CA2569788A1 (en)	2005-12-22
AU2005252275A1 (en)	2005-12-22
IL179891A (en)	2014-07-31
US8383117B2 (en)	2013-02-26
IL179891A0 (en)	2007-05-15
US8969540B2 (en)	2015-03-03
CA2569788C (en)	2014-03-18
US20130217865A1 (en)	2013-08-22
EP1766017B1 (en)	2015-01-21
US20070292441A1 (en)	2007-12-20
WO2005121341A1 (en)	2005-12-22
EP1766017A1 (en)	2007-03-28
ES2535229T3 (en)	2015-05-06
CN101044242A (en)	2007-09-26
JP2012187104A (en)	2012-10-04
JP5026268B2 (en)	2012-09-12
EP2927322A1 (en)	2015-10-07
CN101044242B (en)	2013-10-30
PL1766017T3 (en)	2015-08-31

Legal Events

Date	Code	Title	Description
2007-02-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2007-03-28	17P	Request for examination filed	Effective date: 20070108
2007-03-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2007-07-18	RIN1	Information on inventor provided before grant (corrected)	Inventor name: CHAHAL, FRANCINA, C. Inventor name: ENTWISTLE, JOYCELYN Inventor name: MACDONALD, GLEN, CHRISTOPHER Inventor name: BOSC, DENIS, GEORGES Inventor name: GLOVER, NICHOLAS, RONALD Inventor name: CIZEAU, JEANNICK
2007-09-19	DAX	Request for extension of the european patent (deleted)
2009-12-02	A4	Supplementary search report drawn up and despatched	Effective date: 20091104
2010-05-19	17Q	First examination report despatched	Effective date: 20100419
2012-09-05	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: VIVENTIA BIOTECHNOLOGIES INC.
2014-09-17	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2014-10-15	INTG	Intention to grant announced	Effective date: 20140918
2014-11-26	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: VIVENTIA BIO INC.
2014-12-13	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2015-01-02	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2015-01-21	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
2015-01-21	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2015-01-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2015-02-11	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2015-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 707704 Country of ref document: AT Kind code of ref document: T Effective date: 20150215
2015-03-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602005045721 Country of ref document: DE Effective date: 20150305
2015-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH
2015-05-06	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2535229 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150506
2015-06-10	REG	Reference to a national code	Ref country code: NL Ref legal event code: VDEP Effective date: 20150121
2015-06-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 707704 Country of ref document: AT Kind code of ref document: T Effective date: 20150121
2015-06-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2015-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150421 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2015-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150521 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150422
2015-08-31	REG	Reference to a national code	Ref country code: PL Ref legal event code: T3
2015-10-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602005045721 Country of ref document: DE
2015-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2015-11-27	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2015-11-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2015-12-30	26N	No opposition filed	Effective date: 20151022
2016-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2016-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150610
2016-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2016-06-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12
2016-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20160629 Year of fee payment: 12 Ref country code: GB Payment date: 20160627 Year of fee payment: 12 Ref country code: ES Payment date: 20160627 Year of fee payment: 12 Ref country code: CH Payment date: 20160627 Year of fee payment: 12
2016-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20160628 Year of fee payment: 12 Ref country code: PL Payment date: 20160524 Year of fee payment: 12
2016-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20160628 Year of fee payment: 12 Ref country code: IT Payment date: 20160627 Year of fee payment: 12
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050610
2017-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2018-01-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602005045721 Country of ref document: DE
2018-01-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2018-02-28	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20170610
2018-03-21	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2018-03-30	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20180228
2018-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170610 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180103 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170610
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170610 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630
2018-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150121
2018-11-14	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20181114
2019-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170610
2019-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170611

Publication	Publication Date	Title
IL179891A0 (en)	2007-05-15	Tumor specific antibody
HK1218126A1 (en)	2017-02-03	Anti-ilt7 antibody ilt7
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
IL228032A0 (en)	2013-09-30	Antibodies
IL187106A (en)	2015-10-29	Sclerostin-binding antibody
IL190472A0 (en)	2008-11-03	Anti-glypican-3 antibody
GB0503546D0 (en)	2005-03-30	Antibody
GB0517487D0 (en)	2005-10-05	Antibodies
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
GB0401876D0 (en)	2004-03-03	New use for cancer antigen
EP1780221A4 (en)	2007-10-03	Anti-synoviolin antibody
EP1896047A4 (en)	2009-07-22	Anti-gfralpha3 antibodies
GB0505489D0 (en)	2005-04-20	Antibodies
GB0418415D0 (en)	2004-09-22	Antibody
GB0420771D0 (en)	2004-10-20	Antibody
GB0512278D0 (en)	2005-07-27	Antibodies
GB0505054D0 (en)	2005-04-20	Antibodies
GB0407587D0 (en)	2004-05-05	Cancer associated antigens
GB0402641D0 (en)	2004-03-10	Antibodies
GB0402642D0 (en)	2004-03-10	Antibodies
GB0413479D0 (en)	2004-07-21	Novel antibodies
SI1951759T1 (en)	2010-08-31	Anti-egfr antibodies
GB0500400D0 (en)	2005-02-16	Antibody